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Surgical Outcomes of Patients with Neuroblastoma in a
Tertiary Centre in Hong Kong: A 12-year Experience
IHY CHAN, KKY WONG, GCF CHAN, PKH TAM
Abstract Introduction: Neuroblastoma has a heterogeneous clinical course. The prognosis varies widely depending
on the age of diagnosis, extent of disease and tumour biology. However, the specific clinical outcome of
this disease in Hong Kong has not been well characterised thus far. Complete tumour excision has been
demonstrated to confer survival benefit on patients with advanced disease even if there is metastasis.
Since year 2004, we have adopted a revised, more aggressive surgical approach in managing these patients.
Here, we aim to review our experience in the management of this disease. Methods: A retrospective
review was performed for the past 12 years to include all patients who presented with neuroblastoma in
our institution. Data such as the survival, age at diagnosis, MYCN amplification status, the extent of
tumour excision, and stage of the disease were recorded and analysed. Results: 37 patients were included
in this study. Overall survival of our patients was 67.6%. Patients with Stage 1, 2 and 4S have 100%
survival whereas stage 4 patients only have 41.4% survival. Since our revised surgical approach in 2004,
patients who had been operated had a better survival. Survival of stage 4 patients with operation after
2004 was 57.1% whereas the survival of patients at the same stage before 2004 was only 30%. Age at
diagnosis, completeness of tumour excision and stage of disease are also correlated with overall prognosis.
Further, patients with the presence of MYCN gene amplification have apparently poorer survival but it is
not statistically significant due to the small sample size. Conclusion: The management of patients with
neuroblastoma remains a challenge. Advanced stage of disease, incomplete tumour excision and increased
age at diagnosis were all associated with poor survival. We demonstrated a better survival for those who
underwent a more aggressive surgical approach, though this is a technically demanding and time consuming
procedure. Thus, the management of advanced neuroblastoma should be centralised in a centre with
combined surgical, oncological and paediatric intensive care expertise.
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Introduction
Neuroblastoma is a childhood neoplasm which arises
from neural crest cell. It is one of the most common solid
tumours in childhood and accounts for more than 7% of
malignancies in patients younger than 15-year-old in the
United States.1 It most commonly arises from the adrenal
medulla, but can occur anywhere along the sympathetic
chain from neck to pelvis.
Neuroblastoma has a diverse clinical behaviour.
Spontaneous regression of the tumour occurs in a subgroup
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of patients, especially those who are diagnosed before
1 year of age.2 Nonetheless, many patients who have
advanced disease will end up in mortality despite aggressive
multimodal management. Several factors have been
identified to correlate with a favourable clinical outcome.
These include age younger than 1 year at presentation, and
complete tumour excision.3 On the other hand, poor
prognostic factors include advanced stage, older age, MYCN
amplification, tumour cell ploidy and chromosomal
abnormalities.4
With improved understanding of the disease, tumour
biology has been recognised as important factor which
affects survival. Indeed, a Neuroblastoma Grouping System,
which is based on the International Risk Grouping System,
has been developed by the Children's Oncology Group to
stratify each patient's risks.5 Patients are categorised into
low, intermediate and high-risk according to the stage, age
at diagnosis, histopathology, MYCN amplification and DNA
index. Risk-based treatment is then stratified according to
the risk factors.
The overall survival rate of patients with the disease
remains suboptimal, especially for those with advanced
disease. For the high risk group, the long-term survival rate
is less than 40% in most studies.6,7 From the experience of
other tertiary centres, complete excision of tumour would
correlate with better survival.8-11 Recognising this fact and
also with better surgical experience, we started from 2004
to perform gross total excision if possible for all patients,
even in those with advanced disease. Our protocol consists
of 4-5 courses of chemotherapy pre-operatively to shrink
the size of tumour and render it less vascular. We will then
attempt complete or 'near complete' excision even when
the tumor is encasing the major vessels e.g. aorta, inferior
vena cava and branches. This is definitely a high risk
procedure and demands meticulous and expert surgical
techniques. Since there is such a wide variation in outcome
in neuroblastoma patients, local survival data is of
paramount importance for parental counseling and
formulating treatment goals. In this article, we aimed to
investigate the clinical outcome in relation to the surgical
approach for this disease in our centre. The association
between survival and other confounding clinical factors was
also analysed.
Methods
This is a retrospective review of all patients with
neuroblastoma admitted to our centre from January 1996
to April 2008. A total of 41 patients with confirmed
diagnosis of neuroblastoma were identified and their
hospital records were retrieved. Four patients were lost from
follow up and were excluded from the study. As a result 37
patients were included in this study. Fisher's Exact test,
Chi Square test and Kaplan-SMeier survival curve were
used for data analysis. Significance is set at 95% confidence
interval (p<0.05).
We defined 'complete excision' as gross tumour removal
with no macroscopic tumour residue after the operation.
Our protocol consists of 4-5 courses of chemotherapy pre-
operatively, before attempting complete excision. The
chemotherapy for localised tumours was of low intensity
(modified POG low intensity regimen) whereas the
chemotherapy for the advanced stage disease was of high
intensity (modified N6 or N7 protocol of MSKCC). After
surgery, further therapy will be given according to the risk
group of the patients.
For the surgical technique, we adopted an approach first
described by Kiely.12 Briefly, an upper transverse incision
was made in the abdomen. The ascending colon and
duodenum were mobilised and reflected medially for
tumours located on the right side. For advanced disease,
the tumour usually wraps around the inferior vena cava.
The cava was exposed and the lower limit of the tumour
was approached. The tumour was split from the anterior
side starting from the distal margin to proximal, taking
care not to injure the IVC below. Any tumour vessels
encountered were ligated and divided. After splitting the
tumour, the anatomical relationship of vital structures
became clearer for further safe tumour resection. For left-
sided tumours, the descending colon was mobilised and
reflected. Here, the tumour is usually found wrapping
around the aorta. The approach in these cases is similar to
right-sided tumours (Figure 1).
Results
The demographic data of the 37 patients was presented
in Table 1. The mean age at diagnosis was 28.3 months
(range 0-84 months). The mean duration of follow up was
58.3 months (range 8-141 months). The commonest
primary site is in the adrenal gland (18 out of 37 patients),
followed by the retroperitoneum (13) and thorax (4). One
patient presented with primary tumour in the neck and one
in the pelvis respectively. There were two patients with stage
4S disease and they were only treated with low intensity
chemotherapy.
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Disease stage was assigned according to the International
Neuroblastoma Staging System (INSS). The cohort of
patients was mostly diagnosed at more advanced stages.
28 out of 37 patients (75.7%) were diagnosed with stage 3
or 4 disease. The distribution of stage and survival was
illustrated in Table 2. Figure 2 illustrates CT scan findings
of a typical patient under the protocol of aggressive surgery
pre- and post-operatively. Figure 3 shows the anatomy of
the major vasculature after total tumour removal.
The overall survival was 67.6%, with the survival curve
plateauing off at around 60 months after diagnosis. There
was no mortality in all patients with stage 1, 2 or 4S diseases;
whereas the survival of patients with stage 4 disease was
only 41.1%. There was significant correlation between the
stage of disease and survival (p=0.03) (Figure 4).
The mean age at diagnosis for survivors and non-
survivors were 22.8±20.3 months and 39.75±24.0 months
Table 1 Demographic data for patients with neuroblastoma
Male: Female  27:10
Mean age at diagnosis  28.3±22.7 months
Primary site
Adrenal 18 48.60%
Retroperitoneal 13 35.10%
Thorax 4 10.80%
Others 2 5.40%
Total 37
Table 2 Survival rates at different stages of disease
Stage No. of patients No. of deaths Survival rate
1 2 0 100.0%
2 5 0 100.0%
3 11 2 81.8%
4 17 10 41.1%
4S 2 0 100.0%
Total 37 12 67.6%
Figure 2 (a) This is a CT scan picture showing tumour mass encasing aorta and in close proximity of inferior vena cava (IVC) and other
important vessels. (b) This is a CT scan picture showing status after operation. There is no more tumour mass around the major vessels.
Figure 1  This is a schematic diagram showing a neuroblastoma
wrapping around the major vessels.
(a) (b)
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respectively, which is significantly different (p<0.05). As
reported in the literature, younger age at diagnosis,
especially for those less than one year of age, would confer
better prognosis. If one year of age was used as the cut-off,
the survival was much better for patients who were less
than 1 year of age at the time of diagnosis (Table 3). The
mortality rate of patients who were diagnosed with the
disease later than one-year-old was 40% while it was only
16.6% for those who were diagnosed younger than one-
year-old. Though there was no significant difference in the
survival in the 2 groups (p=0.15), this may be due to the
overall small number of patients included in the calculation.
Figure 3 This picture shows abdominal vasculature after tumour
dissection.
Figure 4 Survival curve of neuroblastoma with different stages (1996-2008).
Table 3 Survival of patients according to age
Age Non-survivors Survivors Total
<1 2 10 12
>1 10 15 25
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Thirty-five out of 37 patients were operated on. One
patient was operated in another centre. As a result, the
completeness of tumor excision could not be ascertained.
When we compared the survival of patients who had
complete tumor excision with those who did not, there was
significant improved survival (p<0.001), with the survival
rate approaching 91% in patients with complete tumor
excision (Figure 5). When we divided all the patients into
those who had operation before or after 2004, there were
14 patients who had operation after 2004 and 23 patients
before 2004. The completeness of surgical resection in
patients with stage 3 and 4 patients was illustrated in Table
4. All stage 1 and 2 patients had complete resection from
both periods. All 5 stage 3 patients had complete resection
with the new approach whereas only half of the patients
had complete resection before 2004. As for stage 4 disease,
more patients had complete resection with the new
approach. Since early stage neuroblastoma patients are
known to have good prognosis, we then looked at the data
of patients with stage 4 diseases only. The survival rate is
Table 4 Completeness of tumour resection in stage 3 and 4
patients with the new and old approach
Before 2004 After 2004 Total
Stage 3 complete 3 5 8
incomplete 3 0 3
Total 6 5 11
Stage 4 complete 3 4 7
incomplete 6 3 9
unknown 1 0 1
Total 10 7 17
again higher in stage 4 patients with the new approach at
57.1% and only 30% in stage 4 patients with operation
before 2004, though this is not statistically significant on
log rank test of the Kaplan-Meier survival curve. The
survival curves which compare the new and old approach
for stage 3 and 4 patients were shown on Figures 6 and 7
Figure 5 Survival curve of patients with complete and incomplete tumour excision.
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Figure 6 Comparison of stage 3 patients with new and old approach. It shows 100% survival of stage 3 patients
with the new approach after 2004. The overall survival rate for the old approach was 66.7%.
Figure 7 Comparison of stage 4 patients with new and old approach. The overall survival of new approach is
slightly better than the old approach though it is not statistically significant.
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respectively. With the new approach, stage 3 patients had
100% survival till now. In addition, the local relapse rate
of those who underwent gross total resection was extremely
low whereas patients with gross residual disease often
relapsed locally with or without systemic relapse. Using
the new approach, we encountered 2 intra-operative
complications from 2004 to 2008. They were injury to aorta
and renal vein respectively since neuroblastomas are known
to encasing major vessels. Both of them were repaired with
no long term complications so far.
For MYCN amplification status, it was examined in 12
of our patients. 2 out of 4 patients (50%) with positive
MYCN amplification died whereas only 2 out of 8 patients
(25%) with negative MYCN amplification died (Table 5).
Statistical analysis could not be performed as the number
of patients was too small. However, MYCN amplification
is a known prognostic factor which is associated with poor
survival especially for non-stage 4 patients.13,14
Discussion
According to the data of the Hong Kong Cancer Registry,
the trend of sympathetic nervous system tumour was static
from year 2001 to 2005. Thus, around 7-9 new cases were
diagnosed every year in Hong Kong in this period.15
Neuroblastoma is one of the most common solid tumours
in childhood. Variable clinical course is observed from
spontaneous tumour regression (as in infant with stage 4S
disease), tumour maturation to a benign histologic form
(as in infant with stage 4S disease or incidentally diagnosed
localised tumour), to another extreme of uncontrollable
metastasis.
Risk classification and treatment stratification are very
important in deciding the most appropriate treatment for
individual patients with neuroblastoma. Much effort has
been given to find predictive factors to clarify clinical
outcomes and hence to guide the treatment. The stage of
the disease, the age at diagnosis, and MYCN oncogene
amplification, and Shimada histological grading have all
been documented as prognostic factors and are currently
used in The International Neuroblastoma Classification
System.16 Treatment stratification will be based on these
prognostic factors ranging from low intensity chemotherapy
to intensive multi-modality approaches. Aggressive surgery
is an important part of management in most of these
patients.
Some investigators found better survival for those
patients who received complete excision.10,11 Our experience
is also in line with these findings. We did demonstrate better
survival on patients with aggressive approach especially
on stage 3 patients. Though the survival benefit is not
statistically significant, we think the short follow up time
and the small number of patients can account for this. And,
this is the limitation in our study in comparing the 2 groups
with different follow up time. We still look forward for the
long term outcome of this new approach. However, we have
also experienced intra-operative complications as
previously reported by Kiely.16 This high-lights the technical
demand of this operation. Despite this, we have not thus
far encountered immediate post-operative mortality from
this aggressive surgical approach. Taken all points together,
we would suggest that management of patients with
advanced stage neuroblastoma should be concentrated in a
centre with excellent surgical, oncological and intensive
care support.
In this article, we demonstrated that survival rate of
neuroblastoma patients in Hong Kong was similar to those
reported in other developed countries. The improvement
in survival is contributed by multiple factors including
improvement in supportive care, enhanced surgical
technique and multimodal therapeutic approaches including
chemotherapy, immunotherapy and megatherapy with
autologous haemopoietic stem cells transplantation.
However, even with these multimodal approaches, the
outcome of patients with stage 4 disease remained
suboptimal. Exploration of more novel therapeutic
approaches is required to further improve the outcomes of
patients with advanced stage metastatic neuroblastoma.
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